Enovis CEO Trerotola signs retirement transition; will serve as Special Advisor for 1 year post-successor

Enovis CORP

CEO Matthew Trerotola's retirement effective when successor appointed; transition agreement signed March 13, 2025.
He will serve as Special Advisor for one year after Appointment Date, receiving current $1,077,000 base salary for two months then reduced (min 50%).
No further equity or long-term incentive awards; outstanding awards continue per retirement provisions in equity agreements.
Non-compete applies for two years after Retirement Date in orthopedic and medical device business; non-solicitation and non-disparagement also in place.
Successor CEO has not yet been named by the Board.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Matthew L. Trerotola

Chief Executive Officer

ENOV · Enovis CORP

Filed: March 14, 2025, 7:59 PM ET

As previously announced by Enovis Corporation (the “Company”), on February 25, 2025, Matthew L. Trerotola notified the Board of Directors (the “Board”) of the Company of his intention to retire from his current position as Chief Executive Officer (“CEO”) of the Company, effective upon his successor being appointed by the Board and assuming the position as CEO of the Company (the “Appointment Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Matthew L. Trerotola changed role as Chief Executive Officer at Enovis CORP.

Action: retire
Role: Chief Executive Officer

Exact text from the filing

As previously announced by Enovis Corporation (the “Company”), on February 25, 2025, Matthew L. Trerotola notified the Board of Directors (the “Board”) of the Company of his intention to retire from his current position as Chief Executive Officer (“CEO”) of the Company, effective upon his successor being appointed by the Board and assuming the position as CEO of the Company (the “Appointment Date”).

View on SEC.gov

Enovis CORP filing history →

Source: SEC EDGAR

accession 0001193125-25-054845

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.